Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCLC | P48506 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.49 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870212 | 0.83 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4869321 | 0.83 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4869112 | 0.78 | ERAP2 (0.46) | FOLH1 | |
| SCHEMBL4872905 | 0.76 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL14112046 | 0.76 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4869930 | 0.76 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4868941 | 0.76 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4871210 | 0.76 | FOLH1 (0.50) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL4875386 | 0.74 | FOLH1 (0.51) | GCLCFOLH1GRM3NAALAD2 | |
| SCHEMBL18647063 | 0.73 | GRM3 (0.82) | FOLH1GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | GCLC 124/4885FOLH1 70/4885GRM3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.